Desentum Raises €28M for Allergy Vaccines

Finnish biotech Desentum has raised €28 million to advance allergy treatments designed to reduce adverse reactions while making immunotherapy more practical.

What happened

Desentum closed an oversubscribed €28 million equity financing arranged by Springvest. The company is developing genetically engineered allergen-based treatments aimed at controlling the immune response to substances including birch pollen, peanuts and cats. Its leading birch-pollen programme is being evaluated in Phase II clinical trials, with results expected later in 2026. The financing provides resources to continue clinical work and advance additional programmes. The technology is investigational: its candidates have not received approval for commercial use, and clinical efficacy remains to be established.

Why it matters

Conventional allergy immunotherapy can require repeated treatment over years and may itself trigger allergic reactions. Desentum's development strategy is to modify the relevant proteins so that treatment could potentially be delivered more safely or efficiently while still producing a protective immune response. If successful, that would address both clinical limitations and practical barriers to patient adoption.

The bigger picture

Biotech investors continue to support targeted approaches that improve on established treatment categories rather than replacing them entirely. For Desentum, the near-term value of the business rests less on the headline financing than on high-quality clinical evidence. Trial results will determine whether the proposed biological mechanism translates into meaningful benefits for patients.